Epidemiology of infection in AML: A European Hematology Association survey (EPIAMLINF)
Project team
Jon Salmanton-García
Institution: University of Cologne, Germany
Biography: My research focuses on infectious diseases in hematology, particularly fungal infections and viral complications in immunocompromised patients.
As the scientific coordinator of the EPICOVIDEHA registry, I oversee a global initiative studying respiratory viral infections in hematological patients. This work has provided valuable insights into disease burden, risk factors, and treatment strategies, ultimately improving patient care.
Livio Pagano
Institution: Policlinico Universitario Fondazione Agostino Gemelli, Italy
Biography: My research primarily focuses on infectious complications in hematologic malignancies, with a strong emphasis on fungal infections.
Over the years, I have been involved in multiple international projects that have shaped our understanding of opportunistic infections in immunocompromised patients.
My work integrates clinical data, laboratory findings, and epidemiological trends to develop risk stratification models and optimize antifungal stewardship.
Oliver A. Cornel
Institution: Biomedical scientist
Biography: My research focuses on clinical infectious diseases, particularly the development of diagnostic and therapeutic strategies for invasive fungal infections.
As Professor of Medicine and Translational Research at the University of Cologne, I lead international initiatives aimed at improving the management of fungal diseases in immunocompromised patients.
I founded FungiScope, a global registry for rare fungal infections, and have coordinated major clinical trials shaping antifungal treatment paradigms.
Project aims
Jon Salmanton-García's summary
The EHA grant will allow us to expand the scope of the epidemiology of infections in the AML project.
We will:
- Enhance data collection across multiple European centers
- Strengthen collaboration within the Infections in Hematology network
- Generate impactful findings that will provide essential insights for optimizing infection prevention and treatment strategies in AML patients undergoing chemotherapy
Moreover, this support will help me consolidate my role in European hematology-infection networks and develop new collaborations. By leveraging this opportunity, I aim to refine diagnostic and therapeutic approaches, ensuring better outcomes for patients facing life-threatening infections.
Livio Pagano's summary
This EHA grant will provide crucial support to further investigate the impact of emerging pathogens in hematology. In particular, it will allow us to:
- Refine early diagnostic strategies
- Evaluate best antimicrobial therapies
- Assess the long-term outcomes of affected patients
With this funding, I will also enhance international collaborations and facilitate multicenter studies aimed at improving patient management. By fostering stronger partnerships within the hematology-infection community, we can ensure the timely translation of research findings into clinical practice.
Oliver A. Cornely's summary
The EHA grant will support research on precision medicine strategies, tailoring antimicrobial therapy to individual patient profiles. Additionally, this funding will enhance our ability to conduct multicenter studies, ensuring real-world evidence-based advancements in patient care.
Beyond research, this grant will foster training initiatives for early-career scientists and clinicians, ensuring the next generation is equipped to tackle infectious complications in hematology.
Strengthening European collaborations will further drive impactful discoveries in infectious diseases and hematology, ultimately improving outcomes for immunocompromised patients worldwide.
Back